AstraZeneca: disappointed by cancer treatment results

(CercleFinance.com) - Anglo-Swedish pharmaceuticals company AstraZeneca said that it is disappointed by the results of a stage III trial for an advanced head and neck cancer treatment.


In the study, Imfinzi monotherapy and the combination of Imfinzi plus tremelimumab did not meet the primary endpoints of improving overall survival compared to chemotherapy in hard-to-treat patients who experienced disease progression following chemotherapy.

"While these results are disappointing, we remain committed to evaluating the potential of Imfinzi and other innovative medicines for patients with head and neck cancer," said Sean Bohen, AstraZeneca's Chief Medical Officer.

Yet, AstraZeneca shares were trading higher in morning trading, adding 0.7% at 5,995 pence.

Copyright (c) 2018 CercleFinance.com. All rights reserved.